These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26686455)

  • 1. Induction Therapy for Mesothelioma.
    Opitz I; Weder W
    Semin Thorac Cardiovasc Surg; 2015; 27(2):240-9. PubMed ID: 26686455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
    Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
    Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel induction therapies for pleural mesothelioma.
    Donahoe L; Cho J; de Perrot M
    Semin Thorac Cardiovasc Surg; 2014; 26(3):192-200. PubMed ID: 25527013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
    de Perrot M; Feld R; Leighl NB; Hope A; Waddell TK; Keshavjee S; Cho BC
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):468-73. PubMed ID: 26614413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
    Frischknecht L; Meerang M; Soltermann A; Stahel R; Moch H; Seifert B; Weder W; Opitz I
    J Thorac Cardiovasc Surg; 2015 Jun; 149(6):1539-46.e1. PubMed ID: 25840756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.
    Baldini EH; Richards WG; Gill RR; Goodman BM; Winfrey OK; Eisen HM; Mak RH; Chen AB; Kozono DE; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2015 May; 149(5):1374-81. PubMed ID: 25772281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk?
    Mordant P; McRae K; Cho J; Keshavjee S; Waddell TK; Feld R; de Perrot M
    Eur J Cardiothorac Surg; 2016 Sep; 50(3):433-8. PubMed ID: 27005976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience.
    Miyazaki T; Yamasaki N; Tsuchiya T; Matsumoto K; Kamohara R; Hatachi G; Nagayasu T
    Ann Thorac Cardiovasc Surg; 2018 Apr; 24(2):81-88. PubMed ID: 29367501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical Risk and Survival Associated With Less Invasive Surgery for Malignant Pleural Mesothelioma.
    Hasegawa S; Kondo N; Matsumoto S; Takuwa T; Hashimoto M; Kuroda A; Nakamichi T; Kamikonya N; Tsujimura T; Nakano T
    Semin Thorac Cardiovasc Surg; 2019; 31(2):301-309. PubMed ID: 30639549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleural mesothelioma: is the surgeon still there?
    Opitz I; Weder W
    Ann Oncol; 2018 Aug; 29(8):1710-1717. PubMed ID: 29905765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Return to intended oncologic treatment after surgery for malignant pleural mesothelioma.
    Nelson DB; Rice DC; Mitchell KG; Tsao AS; Gomez DR; Sepesi B; Mehran RJ
    J Thorac Cardiovasc Surg; 2019 Sep; 158(3):924-929. PubMed ID: 31430846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
    Soldera SV; Kavanagh J; Pintilie M; Leighl NB; de Perrot M; Cho J; Hope A; Feld R; Bradbury PA
    Oncologist; 2019 Jul; 24(7):e510-e517. PubMed ID: 30478189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.
    Verma V; Ahern CA; Berlind CG; Lindsay WD; Grover S; Friedberg JS; Simone CB
    J Thorac Cardiovasc Surg; 2019 Feb; 157(2):758-766.e1. PubMed ID: 30454981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: the "SMART" approach for resectable malignant pleural mesothelioma.
    Cho BC; Feld R; Leighl N; Opitz I; Anraku M; Tsao MS; Hwang DM; Hope A; de Perrot M
    J Thorac Oncol; 2014 Mar; 9(3):397-402. PubMed ID: 24445595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of proliferative indices in surgically resected IIIA-N2 non-small cell lung cancer after induction chemotherapy.
    Corzani R; Luzzi L; Spina D; Voltolini L; Paladini P; Ghiribelli C; Ghisalberti M; Borrelli R; Meniconi F; Monaci N; Gotti G
    J Cardiovasc Surg (Torino); 2017 Oct; 58(5):763-769. PubMed ID: 24740119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early-stage Clinical Characterization of Malignant Pleural Mesothelioma.
    Negi Y; Kuribayashi K; Funaguchi N; Doi H; Mikami K; Minami T; Takuwa T; Yokoi T; Hasegawa S; Kijima T
    In Vivo; 2018; 32(5):1169-1174. PubMed ID: 30150440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
    Flores RM; Pass HI; Seshan VE; Dycoco J; Zakowski M; Carbone M; Bains MS; Rusch VW
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):620-6, 626.e1-3. PubMed ID: 18329481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy.
    Frick AE; Nackaerts K; Moons J; Lievens Y; Verbeken E; Lambrecht M; Coolen J; Dooms C; Vansteenkiste J; De Leyn P; Nafteux P
    Eur J Cardiothorac Surg; 2019 May; 55(5):934-941. PubMed ID: 30535191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.